Next Generation Biologics for Cancer Therapy: Beyond the Success of Conventional Monoclonal Antibodies

Moderator: Mike Rice, Senior Consultant, Defined Health

Panelists:

- Christian Zahnd, PhD, Chief Executive Officer, Molecular Partners AG
- John Haurum, MD, PhD, Chief Executive Officer , F-star
- Hans-Peter Gerber, PhD, Executive Director, Pfizer
- John M. Lambert, Ph.D, Executive Vice President & Chief Scientific Officer, ImmunoGen, Inc.
- Bill Grossman MD, PhD, Senior Vice President of Research & Development, Biothera

CANCER PROGRESS by Defined Health

F-star

BISPECIFIC. BY DESIGN.

Advancing Novel Bispecific Antibody Biologics

March 2013

Systematic Screening for Synergistic Combinations



Symphogen: Koefoed et al, mAbs 2011;3:584-95

Main Bispecific Issues

- Greatest challenge is to find the right combination leading to enhanced efficacy, durability of response, and safety
- Not any combination of “best mAb” will work
- Druggability issues
  - Manufacturability
  - Stability & PK
- The bispecific preferably contributes additional biology not achieved with the combination (efficacy improvement)
  - Synergistic, dual pathway blockade
  - Immune effector function recruitment
  - Tissue targeting of second antibody
- Need to focus on biological hypothesis testing

Fcabs: at the heart of Modular Antibody Technology

- Drug-like characteristics:
  - Similar potency to a full-length antibody
  - Binds Fc receptors
  - Mobilises immune effector functions



mAb^2: speed in unlocking novel biology through modularity



mAb^2: A genuine bispecific mAb

- Looks like a mAb
  - comparable structure
- Works like a mAb
  - retains all antibody functionality
- Behaves like a mAb
  - maintains manufacturing characteristics
- Performs beyond a mAb
  - synergy through bispecificity
- Well-established regulatory path



mAb^2 rapidly generated from Fcab



- Optimum modality currently being identified
- Program to be progressed internally

Summary

- Powerful modular bispecific antibody platform
- CMC challenges identical to mAb
- Lead program funded to IND filing
- Multiple opportunities for building value through partnerships

john.haurum@f-star.com